Anxiolytics and Sedative-Hypnotics Toxicity

Etiology

The most common causes of anxiolytic and sedative toxicity include inappropriate dosing, medication misuse or abuse, intentional overdose, and clinically significant drug–drug interactions. Older adults and patients with hepatic or renal dysfunction are particularly vulnerable because impaired drug metabolism or excretion may result in medication accumulation and prolonged sedative effects, increasing the risk of excessive sedation, falls, respiratory depression, and cognitive impairment. Toxicity may also occur when cytochrome P450 (CYP) inhibitors, such as fluvoxamine, impair the metabolism of BZDs such as alprazolam, leading to elevated serum drug concentrations and enhanced CNS depression. Concurrent use of multiple sedating agents, particularly BZDs combined with opioids, substantially increases the risk of accidental overdose and fatal respiratory depression. Coingestion of alcohol with BZDs or barbiturates can further potentiate CNS and respiratory depressive effects, resulting in severe toxicity, coma, or death.

Epidemiology

BZDs are the most commonly abused anxiolytic class. Limited epidemiologic data exist for other agents discussed in this activity. However, BZD misuse occurs most frequently among younger adults, with individuals aged 18 to 49 years accounting for the highest rate of misuse. Adults aged 50 to 65 more commonly receive BZD prescriptions.[1] Lifetime prevalence of anxiolytic and sedative use disorders, including BZDs and barbiturates, is estimated at approximately 1.0% to 1.1% in the US.[2] The prevalence of anxiolytic and sedative use disorder is estimated at approximately 0.16% of the general population and approximately 6% among individuals with concurrent illicit drug use disorder. Risk factors associated with anxiolytic and sedative toxicity include White race, female sex, lack of insurance, unemployment, panic symptoms, concurrent psychiatric symptoms, alcohol use disorder or dependence, cigarette use, illicit drug use, and history of intravenous drug use.[3]

Pathophysiology

BZDs and barbiturates enhance inhibitory signaling at γ-aminobutyric acid (GABA) type A (GABA_A) receptors. These receptors are ligand-gated chloride ion channels that mediate fast inhibitory neurotransmission in the CNS. Activation of GABA_A receptors permits chloride influx, resulting in neuronal hyperpolarization and reduced neuronal excitability. BZDs act as positive allosteric modulators at the BZD binding site and increase the frequency of GABA_A chloride channel opening, whereas barbiturates increase the duration of channel opening and, at higher concentrations, may directly activate the receptor.

Non-BZD hypnotics, such as “Z-drugs” like zolpidem, have different chemical structures but also act at the BZD site of GABA_A receptors, with selectivity for α1-containing GABA_A receptor subtypes. Melatonin receptor agonists act primarily at melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the hypothalamus, modulating circadian signaling and sleep initiation, resulting in drowsiness.

First-generation antihistamines produce sedation mainly through antagonism of central histamine type 1 receptors, often with additional antimuscarinic effects. Opioids act primarily at μ, κ, and δ opioid receptors in the CNS, with μ-opioid receptor activation responsible for much of their analgesia, euphoria, miosis, gastrointestinal hypomotility, and respiratory depression. Opioid-associated reward is thought to involve inhibition of GABAergic interneurons in mesolimbic pathways, resulting in disinhibition of dopaminergic neurons. Respiratory depression is the primary mechanism of opioid overdose-associated mortality, and concurrent use with other sedating substances significantly increases this risk.

Anticonvulsants produce sedation through heterogeneous mechanisms, including enhancement of GABAergic neurotransmission, modulation of glutamate signaling, and sodium or calcium channel effects. Anticonvulsant toxicity may also result from additive CNS depression or pharmacokinetic interactions.

Toxicokinetics

Sedative-hypnotic toxicokinetics vary by drug class, formulation, patient factors, and coingestants. Most agents are rapidly absorbed after oral ingestion and produce toxicity through CNS effects. Duration of toxicity may be difficult to predict because metabolism and excretion may change in overdose compared with therapeutic dosing. Hepatic clearance and formation of active metabolites further influence clinical course.

BZDs differ in elimination half-life and metabolism. Long-acting agents, such as diazepam and chlordiazepoxide, form active metabolites that may cause prolonged sedation. Lorazepam, oxazepam, and temazepam undergo glucuronidation and do not produce clinically important active metabolites.[4][5] Non-BZD sedative-hypnotics, such as zolpidem, are rapidly absorbed after oral ingestion and undergo hepatic metabolism primarily via CYP–mediated oxidation to inactive metabolites. Zolpidem ingestion typically produces short-lived effects. Large ingestions may alter pharmacokinetics, and coingestion of CYP inhibitors may prolong toxicity.

Barbiturates demonstrate variable and complex toxicokinetics. Phenobarbital has a long elimination half-life and may produce prolonged coma in overdose. Long-acting barbiturates may be amenable to enhanced elimination in severe poisoning, including multiple-dose activated charcoal administration and, in rare cases, extracorporeal removal. Melatonin receptor agonists generally undergo 1st-pass metabolism and have relatively short elimination half-lives. First-generation antihistamine sleep aids, such as diphenhydramine, are rapidly absorbed, highly lipophilic, and highly protein bound, with a large volume of distribution. Antimuscarinic effects in overdose may delay gastrointestinal absorption. Large volume of distribution and high protein binding limit the utility of hemodialysis.

History and Physical

The toxidrome associated with anxiolytic or sedative-hypnotic poisoning varies by the causative agent. Many isolated BZD overdoses result in self-limited CNS depression without additional effects, except in larger ingestions. The most common presentation of BZD toxicity is CNS depression with otherwise normal hemodynamics and examination findings. Patients are often drowsy but arousable and capable of contributing to history taking.

Many intentional BZD overdoses involve ethanol coingestion, which potentiates sedative effects and increases the risk of aspiration and respiratory depression. Ethanol coingestion may produce slurred speech, ataxia, and depressed mentation. Severe toxicity may progress to stupor or coma. Non-BZD hypnotic poisoning typically produces a similar presentation. However, this class of medications is more commonly associated with complex sleep-related behaviors, including sleepwalking, sleep-driving, eating, and other activities performed without full awareness. These effects are commonly reported with zolpidem, zaleplon, and eszopiclone.

CNS depression is also a feature of opioid toxicity. However, additional vital sign and examination findings should raise suspicion for opioid toxicity, including depressed respiratory rate, decreased tidal volumes, decreased bowel sounds and gastrointestinal motility, and miotic pupils. Normal pupil examination findings do not exclude opioid toxicity. Bradycardia is common but not universal. Hypotension may also occur. Hypothermia may result from impaired thermogenesis or environmental exposure.

Antihistamines commonly found in over-the-counter sleep aids may produce a distinct toxidrome. Many antihistamines, such as diphenhydramine, produce an antimuscarinic toxidrome characterized by mydriasis, tachycardia, dry mucous membranes or skin, decreased bowel sounds, urinary retention, and delirium or hallucinations.

Antiseizure medications frequently cause sedation, with potential for toxicity due to narrow therapeutic windows. Additional manifestations include slurred speech, dizziness, and ataxia. Serum concentrations of antiseizure medications may assist in identifying toxicity, although the degree of elevation does not consistently correlate with clinical severity.

Evaluation

The history and physical examination are the most important components in the diagnosis of sedative-hypnotic toxicity, rather than any specific laboratory or imaging study. If possible, determination of the ingested drug from the patient or a witness is essential to tailor further evaluation, prognosis, and treatment. History is often unreliable in patients who intentionally ingest medication in a suicide attempt.[6][7] A patient's ability to provide history may also be limited by sedating and psychoactive drug effects. Physical examination should include assessment of mental status, vital signs, pupils, mucous membranes, bowel sounds, skin, and deep tendon reflexes. Absence of other associated toxidromes may suggest sedative-hypnotic ingestion.

An electrocardiogram (ECG) may provide diagnostic and prognostic information, particularly when history is limited. Assessment for QRS and QTc interval prolongation may indicate ingestion of drugs with fast sodium-channel blockade or potassium efflux channel inhibitory properties, respectively. Arterial or venous blood gas analysis may demonstrate clinically occult respiratory depression. Radiographic studies may benefit patients by excluding nontoxicologic causes of CNS depression.

Urine drug testing is of limited utility. Urine drug screens may detect exposure to common prescription and recreational drugs but are associated with false-positive and false-negative results and do not confirm active intoxication due to extended detection windows. Coingestion with other medications is frequent, and evaluation should include testing for common agents such as acetaminophen and salicylates. Additional assessments, including renal function and acid–base status, may assist in prognosis and management.

Treatment / Management

Multiple treatment modalities are available for patients with anxiolytic and sedative-hypnotic poisoning. Initial management should prioritize stabilization of airway, breathing, and circulation, with close attention to hemodynamic and respiratory status. Patients with significant CNS depression may require endotracheal intubation and mechanical ventilation to prevent respiratory failure and cardiopulmonary arrest. Management should be guided by the suspected intoxicating agent, clinical presentation, and presence of coingestants. In most cases, treatment consists primarily of supportive care, continuous monitoring, and prevention of complications. However, specific antidotal therapies may be appropriate in selected situations.

Management of BZD toxicity is primarily supportive unless severe toxicity develops. Airway protection is the highest priority. Patients with significant sedation or hypoventilation may require supplemental oxygen administration, continuous cardiac and end-tidal carbon dioxide monitoring, and mechanical ventilation. Activated charcoal is generally not recommended in isolated BZD overdose due to the increased risk of aspiration in sedated patients.

Flumazenil, a competitive BZD receptor antagonist, may reverse BZD-induced sedation following procedural sedation, anesthesia, or overdose.[8][9] However, the use of this drug is controversial due to the risk of withdrawal seizures in patients with chronic BZD use or coingestion of proconvulsant agents.[10] Careful consideration is required before administration in patients with suspected chronic BZD use and possible dependence. The risk of withdrawal seizure is lower in patients without chronic use. Flumazenil may also reverse toxicity associated with Z-drugs. However, clinical utility in these cases is controversial.

Opioid toxicity remains a major public health concern in many areas and is associated with significant morbidity and mortality due to respiratory depression. Initial management requires prompt assessment and stabilization of airway, breathing, and circulation, with close monitoring for hypoventilation, hypoxia, and hemodynamic instability.

Naloxone, a short-acting opioid antagonist, is the primary antidotal therapy and can rapidly reverse opioid-induced respiratory and CNS depression. Intravenous administration is preferred because of this agent's rapid onset of action. Intranasal, intramuscular, and subcutaneous formulations are also effective when intravenous access is unavailable, although onset and absorption characteristics may vary by route. Naloxone has a shorter duration of action than many opioids, requiring continued observation for recurrent sedation or respiratory depression. Consultation with a poison center or medical toxicologist can provide additional guidance regarding ongoing management, monitoring, and disposition in complex or severe overdose cases.

Management of antihistamine poisoning is primarily supportive. Patients may require additional interventions for antimuscarinic effects, including urinary retention and delirium. Isolated rhabdomyolysis has also been described after antihistamine overdose. Acetylcholinesterase inhibitors, such as physostigmine or rivastigmine, have been used to reverse CNS antimuscarinic effects, although safety concerns remain. The use of these agents should generally be discussed with a poison control center or medical toxicologist.

Differential Diagnosis

The differential diagnosis for anxiolytic and sedative-hypnotic poisoning is broad because many affected patients present with altered mental status, sedation, or obtundation and are often unable to provide a reliable history. The clinical history may be incomplete or misleading in cases of intentional overdose or polysubstance ingestion, requiring a broad diagnostic approach.

The evaluation should consider alternative causes of altered mental status, including metabolic, neurologic, infectious, toxicologic, and structural etiologies. Important alternative diagnoses include hypoglycemia, electrolyte abnormalities, hepatic encephalopathy, sepsis, stroke, intracranial hemorrhage, hypoxia, postictal states, and toxicity from other substances, including carbon monoxide.

Focused physical examination, toxidrome recognition, laboratory studies, ECG, and targeted imaging when indicated are essential for distinguishing sedative toxicity from other life-threatening conditions. Rapid assessment of reversible causes, particularly hypoglycemia using point-of-care glucose testing, is a critical component of the initial evaluation.

Prognosis

The prognosis of anxiolytic and sedative-hypnotic toxicity depends on multiple factors, including the specific agent involved, dose and duration of exposure, presence of coingestants, timeliness of recognition, and time to initiation of appropriate supportive care. Most patients who receive early diagnosis and prompt intervention experience favorable outcomes with minimal long-term sequelae. However, severe overdose, delayed presentation, or polysubstance intoxication, particularly involving CNS depressants like opioids and alcohol, may result in respiratory failure, cardiac complications, neurologic injury, or death. The prognosis is generally worse in patients with significant comorbidities, prolonged hypoxia, or intentional overdose associated with psychiatric illness. Early stabilization, close monitoring, and appropriate interprofessional management are critical to improving clinical outcomes and reducing morbidity and mortality.

Complications

Complications associated with anxiolytic and sedative-hypnotic toxicity range from mild transient sedation to life-threatening respiratory and cardiovascular collapse. Severe overdose may result in respiratory depression, hypoxia, aspiration, cardiac arrhythmias, hypotension, seizures, coma, or death, particularly in cases involving polysubstance use or coingestion with alcohol or opioids. Early recognition and prompt supportive management are associated with favorable outcomes and minimal long-term sequelae in many patients. However, delayed treatment or prolonged hypoxia may lead to permanent complications, which may include cerebral ischemia, anoxic brain injury, cardiac ischemia, cognitive impairment, or multiorgan dysfunction. Secondary complications related to prolonged immobilization, mechanical ventilation, or critical illness may also contribute to increased morbidity, prolonged hospitalization, and mortality.